News ArticlesThe complexity of multi-localizing and multi-functional proteinsChanges in metabolic pathways are frequently seen in cancer cells, and mutations in certain metabolic genes may even play a direct role in cancer development and progression. One gene for which this is true is the multi-localizing gene fumarate hydratase...Read more Reducing uncertainty in drug development: a Q&A with Thomas HelledayT cells are central drivers of inflammation across autoimmune and inflammatory diseases, yet current therapies inadequately target pathogenic T-cell pathways, limiting durable disease control. In a recent study published in Signal Transduction and Targeted Therapy, a team led by Thomas Helleday and Theodora Manolakou, identified a novel, targetable transcriptional-metabolic axis that sustains inflammatory T-cell responses. In an interview by Gustav Ceder, Helleday discusses the novel findings and ongoing lines of research...Read more A protein in the wrong place can be catastrophicAmyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder associated with high morbidity and early mortality. Rapidly progressive cell death of upper and lower motor neurons in the brain as well as in the spinal cord leads to loss of voluntary muscle control. Within a few years of diagnosis, patients lose the ability to move, speak, eat and breath without mechanical support. There is no cure for ALS, with current treatments merely aiming at slowing disease progression and improving symptoms...Read more From spatial proteomics to tissue validation: DHCR7 in early ovarian cancerA recent Molecular Systems Biology study used exploratory spatial proteomics to investigate early changes in high-grade serous ovarian cancer, including precursor lesions in the fallopian tube. In this interview by Gustav Ceder, Dr Fabian Coscia and Dr Mihnea-Paul Dragomir discuss how the team moved from spatial proteomics discovery to tissue-based validation using an Atlas Antibodies / Human Protein Atlas antibody against DHCR7...Read more RNF126 and the dedifferentiation of liver cancerAn article in PNAS describes how hypoxia and the elimination of peroxisomes drives HCC dedifferentiation, a hallmark of malignancy and a challenge for therapy. The E3 ubiquitin ligase RNF126 is identified as a hypoxia-inducible switch that determines peroxisomal fate and links the hypoxic microenvironment to loss of hepatocyte differentiation...Read more |